Functional outcome measures as clinical trial endpoints in ALS
- 23 November 2004
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 63 (10), 1933-1935
- https://doi.org/10.1212/01.wnl.0000144345.49510.4e
Abstract
The topiramate study was a 12-month randomized placebo-controlled trial in patients with ALS. Follow-up evaluation of the placebo group (n = 97) constituted a well-described cohort of patients with ALS, in whom multiple outcome measures were assessed at 3-month intervals. During the 12-month study period, the decline of forced vital capacity (FVC%) and ALS functional rating scale (ALSFRS) was linear, whereas the decline of maximum voluntary isometric contraction–arm (MVIC-arm) and MVIC-grip Z scores was curvilinear. Rates of FVC% and ALFRS decline, but not of MVIC-arm or MVIC-grip, were independent predictors of survival.Keywords
This publication has 12 references indexed in Scilit:
- ALS treatment strikes out while trying for a homerNeurology, 2003
- A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosisNeurology, 2003
- Evaluating surrogate markers of clinical outcome when measured with error.Published by JSTOR ,1998
- Neurological effects of microwave exposure related to mobile communicationJournal of the Neurological Sciences, 1997
- Natural history of ALSNeurology, 1996
- Pulmonary Function at Diagnosis of Amyotrophic Lateral SclerosisChest, 1993
- Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosisNeurology, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958